Press Release

Arlington Scientific, Inc. broadens product portfolio and further expands its product offering through the acquisition of Non-Mammalian Blocking Buffers.

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of EastCoast Bio.  Arlington Scientific will now be the exclusive worldwide manufacturer of these proprietary blocking buffers for markets including In-Vitro Diagnostic (IVD) manufacturers and for research and development institutions.

“This acquisition will provide strategic value to Arlington Scientific in the form of new product markets, expansion of its manufacturing capabilities, increased sales and new customers.  This is in line with ASI’s strategy of being a progressive industry leader through the pursuit of quality products, superior customer service, high corporate values, and a genuine appreciation for each customer,” said David Porter, Chief Business Development Officer for Arlington Scientific.

ASI is an FDA registered establishment with over 36 years of medical device manufacturing expertise in diagnostic reagents and serological test kits.  ASI is at the forefront of innovation and was the first to develop an automated nontreponemal algorithm for the detection of syphilis; the first to develop the only automated nontreponemal (RPR) syphilis analyzer FDA cleared for diagnostic, blood donor screening and cadaveric (non-heart beating) donor screening; the first to include mercury free RPR reagents, implementation of liquid controls, screw cap lids, warp resistant test cards, extended shelf life for reagents and developing in-vitro diagnostic RPR tests for use with CPD and CPDA-1 anticoagulants.

Product Overview:

Press Release